

DPP Models Deliver Modest Weight Loss

BY MARY ANN MOON

FROM HEALTH AFFAIRS

Structured lifestyle interventions based on the U.S. Diabetes Prevention Program's curriculum were effective at promoting clinically significant weight loss of approximately 4% when applied in real-world settings, according to a meta-analysis.

The U.S. Diabetes Prevention Program conducted a clinical trial in 2002 showing that modest weight loss through caloric restriction and increased physical activity reduced the incidence of diabetes in high-risk patients by 58%. Weight loss was found to be the single most important factor in preventing diabetes from developing over the course of 3 years among patients who were at high risk for the disease. For every kilogram of weight lost, the incidence of diabetes decreased by 16%.

"Yet these results have not been 'translated' into routine clinical practice and public health policy," said Dr. Mohammed K. Ali of Emory University, Atlanta, and his associates.

They performed what they described as the first meta-analysis of U.S. studies in which the structured intervention recommended by the Diabetes Prevention Program was applied to high-risk patients in real-world settings. The meta-analysis included 28 studies published in 2003-2011.

In all, 4 were randomized, controlled trials (RCTs), 2 were cluster RCTs, 20 were single-group studies comparing preintervention and postintervention weight, and 2 were nonrandomized, controlled studies.

Most of the studies were conducted in

urban areas. In all, 12 were based in community centers, recreation centers, and church organizations, and 11 were based in health care facilities. The total number of patients was 2,916, and the median study duration was 1 year.

Across all the reviewed studies, the mean weight loss was 3.99%, which is considered clinically meaningful, Dr. Ali and his colleagues said (Health Aff. 2012 [doi:10.1377/hlthaff.2011.1009]).

Weight loss was comparable among programs that used medical and allied health professionals to implement the intervention (average 4.27% weight loss), programs that used lay community educators (3.15% weight loss), and programs that used electronic media-assisted interventions (4.20% weight loss).

Moreover, sensitivity analyses showed that programs with lay community educators achieved greater weight loss

than those with medical and allied health professionals as educators. That finding "has enormous importance for the scalability and economic sustainability of diabetes interventions," Dr. Ali and his colleagues noted, because lay educators required lower salaries and their training was neither costly nor time-consuming.

Programs that included more "core sessions" in which patients received

HER FIRST OSTEOPOROTIC FRACTURE COULD LEAD TO ANOTHER



FORTEO® (teriparatide [rDNA origin] injection) SELECT SAFETY INFORMATION

Prescribe FORTEO only for patients for whom the potential benefits are considered to outweigh the potential risks. FORTEO should not be prescribed for patients at increased baseline risk for osteosarcoma, including those with Paget's disease of bone, unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, or prior external beam or implant radiation therapy. Additionally, patients with bone metastases or a history of skeletal malignancies, metabolic bone diseases other than osteoporosis, or pre-existing hypercalcemia should not receive FORTEO.

Use of FORTEO for more than 2 years during a patient's lifetime is not recommended.

FORTEO CONNECT OFFERS PERSONALIZED SUPPORT TO HELP PATIENTS THROUGHOUT THEIR TREATMENT

- Patients can choose to sign up for insurance investigation, training, and/or ongoing support



Glucose Monitor With Remote Alert

A glucose monitor that can be monitored remotely from another room and is intended for use with a specific insulin pump has been approved by the Food and Drug Administration, the manufacturer, Medtronic, has announced.

A press release issued by the company said that the glucose monitor enables parents or caregivers to monitor the status of an individual's insulin pump and glucose trends, with alerts and alarms that can alert them at their bedside if, for example, the glucose levels of a child or adult sleeping in another room are dropping in the middle of the night.

The device is being marketed as the "mySentry Remote Glucose Monitor," and is used with the MiniMed Paradigm Real-Time Revel System, an insulin pump with a continuous glucose monitor, the Medtronic statement said. At press time, there was no notice of the approval on the FDA's website.

—Elizabeth Mechcatie

Find out how FORTEO forms new bone at www.FORTEOhcp.com

VITALS

Major Finding: The mean weight loss across all 28 studies of lifestyle intervention programs was approximately 4%, which is considered clinically meaningful.

Data Source: A meta-analysis of 28 published U.S. studies (including 2,916 subjects) of lifestyle intervention programs incorporating the findings of the U.S. Diabetes Prevention Program to prevent diabetes by promoting weight loss.

Disclosures: No disclosure information was provided.

The rate of attrition varied greatly among the studies, ranging from 0% to 49%. In some studies that analyzed patient feedback, it appeared that attrition was more strongly related to patients' perceptions of their risk and to their readiness to change than it was to specific features of the intervention, such as the number of counseling sessions. ■

counseling maintained the highest attendance rates. And higher attendance rates correlated positively with greater weight loss.

and to their readiness to change than it was to specific features of the intervention, such as the number of counseling sessions.



COURTESY BILL BRANSON/NATIONAL CANCER INSTITUTE

The weight-loss results of the U.S. Diabetes Prevention Program did not translate in real-world lifestyle interventions based on that DPP model, according to the meta-analysis.

NOW IS THE TIME FOR ANABOLIC ACTION



FORTEO IS INDICATED:

- For the treatment of postmenopausal women with osteoporosis at high risk for fracture
- To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture
- For the treatment of men and women with osteoporosis associated with sustained, systemic glucocorticoid therapy at high risk for fracture

WARNING: POTENTIAL RISK OF OSTEOSARCOMA

In male and female rats, teriparatide caused an increase in the incidence of osteosarcoma (a malignant bone tumor) that was dependent on dose and treatment duration. The effect was observed at systemic exposures to teriparatide ranging from 3 to 60 times the exposure in humans given a 20-mcg dose. Because of the uncertain relevance of the rat osteosarcoma finding to humans, prescribe FORTEO® (teriparatide [rDNA origin] injection) only for patients for whom the potential benefits are considered to outweigh the potential risk. FORTEO should not be prescribed for patients who are at increased baseline risk for osteosarcoma (including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, or prior external beam or implant radiation therapy involving the skeleton).

Please see Important Safety Information and Brief Summary of Prescribing Information on adjacent pages.

FORTEO™
teriparatide (rDNA origin) injection
ANABOLIC ACTION FOR NEW BONE

